Breaking News

You are here » Indian-Commodity  :  Commodities  :  Cardamom  :  Cardamom futures edge higher on MCX

18-Apr2017

Cardamom futures edge higher on MCX

Cardamom futures edged higher on MCX as investors extended their positions amid increase in physical demand for cardamom in the domestic spot market. Further, insufficient supplies on restricted physical arrivals from the major cardamom producing regions too fuelled the uptrend.

The contract for May delivery was trading at Rs 1254.00, up by 0.27% or Rs 3.40 from its previous closing of Rs 1250.60. The open interest of the contract stood at 946 lots.

The contract for June delivery was trading at Rs 1050.00, up by 1.26% or Rs 13.10 from its previous closing of Rs 1036.90. The open interest of the contract stood at 132 lots on MCX.


Related News

View all news

Cardamom futures trade higher on firm demand

Cardamom futures traded higher on MCX, as market players accumulated their bets on low production prospects followed by firm demand from spot domestic markets. Moreover, tight inventory levels after heavy......

Cardamom futures decline on muted demand

Cardamom futures declined on MCX, as market participants trimmed their bets followed by muted demand from physical markets. Meanwhile, concerns about demand from UAE due to strict pesticide rule also weighed......

Cardamom futures tick higher on MCX

Cardamom futures declined on MCX, as speculators widened their positions counting heavy loses to crop amid recent floods. Besides, improved export and spot demand also fuelled the uptrend.The contract......

Top News

View all news

Reliance Power's arm wins arbitration award against NACC

Reliance Power's Wholly Owned Subsidiary -- Sasan Power has won an arbitration award against North American Coal Corporation (NACC). This is a major milestone in this arbitration with the award received......

Tata Steel's arm signs agreement to divest entire stake in Black Ginger 461

Tata Steel's wholly owned indirect subsidiary -- TS Global Minerals Holdings Pte has entered into an agreement to divest its entire stake in its wholly owned step down subsidiary Black Ginger 461 Pty which......

Biocon, Mylan N.V. receive positive approval for Ogivri

Biocon and Mylan N.V. have been issued a positive opinion recommending approval of Ogivri, a biosimilar to Roche's Herceptin (trastuzumab) by the European Medicines Agency's Committee for Medicinal Products......